Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.
J Am Acad Dermatol
; 85(5): 1113-1116, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1466528
Keywords
COVID-19; COVID-19 vaccine; SARS-CoV-2; adalimumab; brodalumab; certolizumab; dermatology; etanercept; glucocorticoid; golimumab; guselkumab; infliximab; ixekizumab; janus kinase inhibitor; mRNA vaccine; methotrexate; mycophenolate; prednisone; risankizumab; rituximab; secukinumab; tildrakizumab; vaccine
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Skin Diseases
/
Biological Products
/
Immunocompromised Host
/
Practice Guidelines as Topic
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
J Am Acad Dermatol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS